In a clinical trial, the drug, acoramidis, had a survival rate of 81 percent after two and a half years, compared to 74 percent among patients who received a placebo, according to a July 17 BridgeBio Pharma news release. The drug also reduced risk of cardiovascular-related hospitalization by 50 percent.
Transthyretin amyloid cardiomyopathy occurs when a “misshapen version of a naturally occurring human protein gets deposited in the heart,” Bloomberg reported. The condition is becoming relatively common with about 5,000 to 7,000 new cases annually. The condition is “increasingly recognized cause of heart failure,” Muriel Finkel, president of Amyloidosis Support Groups advocacy group, told Bloomberg.
The company will file for U.S. market clearance by the end of 2023.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
